Log‐rank test revealed that high FOXC1‐positive stromal cell group (> 18 FOXC1‐positive stromal cells/HPF) and high pERK1‐2‐positive tumor cell group (> 2.5% pERK1‐2 positive tumor cells) was significantly associated with shorter overall and progression‐free survival compared with low FOXC1‐positive stromal cell group (≤ 18 FOXC1‐positive stromal cells/HPF; p = 0.015 and p = 0.034, each respectively; Figure 3A,B) and low pERK1‐2‐positive tumor cell group (≤ 2.5% pERK1‐2‐positive tumor cells; both p = 0.025; Figure 3C,D). This evidence concerns the gene FOXC1 and neoplasm.